scholarly article | Q13442814 |
P50 | author | Eleanor B Schron | Q117272038 |
P2093 | author name string | Albert L Waldo | |
H Leon Greene | |||
John P DiMarco | |||
Scott D Corley | |||
Yves Rosenberg | |||
Andrew E Epstein | |||
D George Wyse | |||
L Brent Mitchell | |||
Andrew D Krahn | |||
Nancy Geller | |||
Richard A Josephson | |||
Lynn Shemanski | |||
Michael J Domanski | |||
Richard C Klein | |||
AFFIRM Investigators | |||
Mary Mickel | |||
Joyce C Kellen | |||
Joy Dalquist Nelson | |||
P433 | issue | 12 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | atrial fibrillation | Q815819 |
P304 | page(s) | 1509-1513 | |
P577 | publication date | 2004-03-08 | |
P1433 | published in | Circulation | Q578091 |
P1476 | title | Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study | |
P478 | volume | 109 |
Q37989837 | 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design |
Q30653045 | 2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures |
Q27341873 | 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society |
Q36446641 | A Simple and Portable Algorithm for Identifying Atrial Fibrillation in the Electronic Medical Record |
Q53383705 | A pilot study to assess benefit of atrial rhythm control after cardiac resynchronization therapy and atrioventricular node ablation. |
Q38654100 | A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial |
Q22306351 | ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation |
Q46734928 | AGEs-RAGE system mediates atrial structural remodeling in the diabetic rat. |
Q37495744 | Ablation of Atrial Fibrillation in the Elderly: Current Evidence and Evolving Trends |
Q81806274 | Ablation of atrial fibrillation: patient selection, technique, and outcome |
Q36867280 | Ablation should not be first-line therapy for the treatment of atrial fibrillation |
Q51062071 | Acute conversion of persistent atrial fibrillation during dofetilide loading does not predict long-term atrial fibrillation-free survival. |
Q38151445 | Addressing the controversy of rate-versus-rhythm control in atrial fibrillation |
Q42777572 | Advances in the Pharmacologic Management of Atrial Fibrillation |
Q34383573 | Advances in the Pharmacological Treatment of Atrial Fibrillation |
Q38076142 | Advances in the management of atrial fibrillation. |
Q38822819 | Anti-arrhythmic strategies for atrial fibrillation: The role of computational modeling in discovery, development, and optimization. |
Q58743469 | Antiarrhythmic drugs for atrial fibrillation: Imminent impulses are emerging |
Q37472036 | Antiarrhythmic drugs for atrial fibrillation: focus on dronedarone |
Q39564664 | Antiarrhythmic properties of ranolazine--from bench to bedside |
Q38124871 | Antiarrhythmic therapy following ablation of atrial fibrillation |
Q97424445 | Applying the CHA2DS2-VASc score to predict the risk of future acute coronary syndrome in patients receiving catheter ablation for atrial fibrillation |
Q28268244 | Arrhythmia-Induced Cardiomyopathies: Mechanisms, Recognition, and Management |
Q87919168 | Arrhythmias: Atrial fibrillation in heart failure - time to revise the guidelines? |
Q36114623 | Association between guideline recommended drugs and death in older adults with multiple chronic conditions: population based cohort study |
Q41988070 | Association of the Ottawa Aggressive Protocol with rapid discharge of emergency department patients with recent-onset atrial fibrillation or flutter |
Q48525838 | Atrial Fibrillation Ablation and its Impact on Stroke. |
Q39300446 | Atrial Fibrillation Ablation: First-Line Therapy? |
Q33574018 | Atrial Fibrillation And Coronary Heart Disease:Fatal Attraction |
Q35901629 | Atrial Fibrillation Management Strategies in Routine Clinical Practice: Insights from the International RealiseAF Survey |
Q37114460 | Atrial Fibrillation and Heart Failure |
Q38597936 | Atrial Fibrillation in Heart Failure US Ambulatory Cardiology Practices and the Potential for Uptake of Catheter Ablation: An National Cardiovascular Data Registry (NCDR®) Research to Practice (R2P) Project |
Q41686261 | Atrial Fibrillation in Heart Failure: a Therapeutic Challenge of Our Times. |
Q37495914 | Atrial Fibrillation in Patients with Ischemic and Non-Ischemic Left Ventricular Dysfunction |
Q34175991 | Atrial antitachycardia pacing and managed ventricular pacing in bradycardia patients with paroxysmal or persistent atrial tachyarrhythmias: the MINERVA randomized multicentre international trial |
Q35292524 | Atrial fibrillation ablation in systolic dysfunction: clinical and echocardiographic outcomes |
Q43012181 | Atrial fibrillation ablation in the real world |
Q37155980 | Atrial fibrillation and congestive heart failure |
Q36836836 | Atrial fibrillation and stroke: the evolving role of rhythm control |
Q33954432 | Atrial fibrillation in congestive heart failure |
Q38032181 | Atrial fibrillation in heart failure |
Q50099027 | Atrial fibrillation in heart failure with preserved ejection fraction: time to address the chicken and the egg. |
Q38153249 | Atrial fibrillation in heart failure: catheter and surgical interventional therapies |
Q26784426 | Atrial fibrillation in heart failure: what should we do? |
Q37882717 | Atrial fibrillation in the aging heart: pharmacological therapy and catheter ablation in the elderly |
Q84856755 | Atrial fibrillation in the elderly |
Q58555771 | Atrial fibrillation reduction by renal sympathetic denervation: 12 months' results of the AFFORD study |
Q39957513 | Atrial fibrillation significantly increases total mortality and stroke risk beyond that conveyed by the CHADS2 risk factors |
Q38006746 | Atrial fibrillation, stroke, and quality of life |
Q37923979 | Atrial fibrillation: an epidemic in the elderly |
Q37476763 | Atrial fibrillation: challenges and opportunities |
Q37483061 | Atrial fibrillation: cure or treat? |
Q34747164 | Atrial fibrillation: current concepts |
Q34986419 | Atrial fibrillation: current perspective |
Q26864877 | Atrial fibrillation: effects beyond the atrium? |
Q37848443 | Atrial fibrillation: pathophysiology and current therapy |
Q37811048 | Atrial fibrillation: what have recent trials taught us regarding pharmacologic management of rate and rhythm control? |
Q37494653 | Atrial-selective sodium channel block for the treatment of atrial fibrillation. |
Q39109570 | Biatrial ablation vs. left atrial concomitant surgical ablation for treatment of atrial fibrillation: a meta-analysis. |
Q41332447 | Blood Pressure and Atrial Fibrillation: A Combined AF-CHF and AFFIRM Analysis. |
Q38469887 | Bucindolol hydrochloride in atrial fibrillation and concomitant heart failure |
Q92840714 | Budget Impact of Cryoablation Versus Radiofrequency Ablation of Atrial Fibrillation in the Brazilian Public Healthcare System |
Q45122374 | CARTO-guided vs. NavX-guided pulmonary vein antrum isolation and pulmonary vein antrum isolation performed without 3-D mapping: effect of the 3-D mapping system on procedure duration and fluoroscopy time |
Q38973172 | CHA2DS2-VASc risk factors as predictors of stroke after acute coronary syndrome: A systematic review and meta-analysis |
Q37761072 | Can ablation prevent the excess mortality of atrial fibrillation? |
Q35954783 | Can atrial fibrillation with a coarse electrocardiographic appearance be treated with catheter ablation of the tricuspid valve-inferior vena cava isthmus? Results of a multicentre randomised controlled trial. |
Q46787245 | Can recent-onset atrial fibrillation be safely and successfully treated with self-administered antiarrhythmic drugs? |
Q33516708 | Can we improve outcomes in AF patients by early therapy? |
Q39300661 | Cardiac Resynchronization Therapy and Atrial Fibrillation |
Q81431685 | Cardiac dimensions and function in atrial fibrillation: how do rate and rhythm control compare? |
Q38201409 | Cardiac potassium channel subtypes: new roles in repolarization and arrhythmia |
Q81388943 | Cardiomyopathy induced by pulmonary vein tachycardia cured by catheter ablation |
Q36584176 | Cardiovascular and non-cardiovascular hospital admissions associated with atrial fibrillation: a Danish nationwide, retrospective cohort study |
Q35790082 | Cardiovascular outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses. |
Q37573899 | Cardioversion for atrial fibrillation: treatment options and advances |
Q35918565 | Catheter Ablation for Atrial Fibrillation in Heart Failure Patients: A Meta-Analysis of Randomized Controlled Trials |
Q60922066 | Catheter Ablation for Atrial Fibrillation in Systolic Heart Failure Patients: Stone by Stone, a CASTLE |
Q42134338 | Catheter Ablation of Atrial Fibrillation - Techniques and Technology |
Q36141391 | Catheter Ablation of Atrial Fibrillation in U.S. Community Practice--Results From Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). |
Q53276291 | Catheter ablation as first-line in atrial fibrillation: is rhythm control finally better than rate control? |
Q36867275 | Catheter ablation as first-line therapy for patients with symptomatic atrial fibrillation |
Q47119395 | Catheter ablation for AF improves global thrombotic profile and enhances fibrinolysis |
Q56986662 | Catheter ablation for atrial fibrillation |
Q31059405 | Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death: data from Swedish health registries. |
Q37546138 | Catheter ablation for atrial fibrillation: a promising therapy for congestive heart failure |
Q38726564 | Catheter ablation of atrial fibrillation in chronic heart failure: state-of-the-art and future perspectives |
Q86575757 | Catheter ablation of atrial fibrillation in patients with heart failure: can we break the vicious circle? |
Q53028592 | Catheter ablation of atrial fibrillation in patients with severely impaired left ventricular systolic function. |
Q38087518 | Catheter ablation of atrial fibrillation to reduce stroke risk |
Q91084221 | Catheter ablation of atrial fibrillation-A key role in heart failure therapy? |
Q80113135 | Catheter ablation of atrial fibrillation: a treatment frontier |
Q35771196 | Catheter ablation of permanent atrial fibrillation: medium term results |
Q27002352 | Catheter ablation versus rate control for atrial fibrillation: what have we learnt from the ARC-HF trial? |
Q42673198 | Chronic digitalis therapy in patients before heart transplantation is an independent risk factor for increased posttransplant mortality |
Q43109711 | Chronotropic Incompetence and Risk of Atrial Fibrillation: The Henry Ford ExercIse Testing (FIT) Project. |
Q57627137 | Clinical Trials on Atrial Fibrillation/Future Perspectives |
Q64069343 | Clinical and Echocardiographic Risk Factors Predict Late Recurrence after Radiofrequency Catheter Ablation of Atrial Fibrillation |
Q64996273 | Clinical characteristics and cardiovascular outcomes in patients with atrial fibrillation receiving rhythm-control therapy: the Fushimi AF Registry. |
Q37538004 | Clinical characteristics, management, and control of permanent vs. nonpermanent atrial fibrillation: insights from the RealiseAF survey. |
Q45267016 | Clinical experience with routine use of a single combined mapping and ablation catheter for isolation of pulmonary veins in patients with paroxysmal atrial fibrillation |
Q45249251 | Clinical trials of antiarrhythmic therapies and optimizing health care resource deployment: the need for a paradigm shift |
Q38095871 | Clinical update on the management of atrial fibrillation. |
Q38666884 | Comorbidity of atrial fibrillation and heart failure |
Q37495724 | Comparing Safety and Efficacy of Irrigated Radiofrequency Catheter Ablation Versus Combined Cryoballoon and Catheter Ablation for Persistent Atrial Fibrillation |
Q84471438 | Comparing ablation and antiarrhythmic drug therapy for atrial fibrillation |
Q36587229 | Comparison of Atrial Fibrillation in the Young versus That in the Elderly: A Review |
Q35772224 | Computational approaches to structural and functional analysis of plastocyanin and other blue copper proteins. |
Q38790389 | Connexin Remodeling Contributes to Atrial Fibrillation |
Q38435600 | Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation. |
Q36590816 | Contact forces during hybrid atrial fibrillation ablation: an in vitro evaluation |
Q38970521 | Contemporary Controversies in Digoxin Use in Systolic Heart Failure |
Q39037010 | Control Of Hypertension Improves The Outcome Of Therapies For Paroxysmal And Persistent Atrial Fibrillation |
Q36374193 | Controversies in atrial fibrillation |
Q43050046 | Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States. |
Q51104318 | Cost comparison of catheter ablation and medical therapy in atrial fibrillation. |
Q35832134 | Cost considerations in the management of atrial fibrillation - impact of dronedarone |
Q36382393 | Cost of atrial fibrillation: invasive vs non-invasive management in 2012 |
Q35885128 | Costs and clinical consequences of suboptimal atrial fibrillation management |
Q37914056 | Cryoablation of atrial fibrillation |
Q81154624 | Curative catheter ablation for atrial fibrillation |
Q36458858 | Current Evidence and Recommendations for Rate Control in Atrial Fibrillation |
Q39300519 | Current Perspectives: Rheumatic Atrial Fibrillation |
Q41835646 | Current ablation strategies for persistent and long-standing persistent atrial fibrillation |
Q46271907 | Current atrial fibrillation guidelines and therapy algorithms: are they adequate? |
Q36072140 | Current issues in atrial fibrillation |
Q42760734 | Current management of atrial fibrillation: rhythm or rate control and thoughts about a new treatment paradigm |
Q46150475 | Current strategies in the treatment of atrial fibrillation |
Q39036995 | Destruction Of Medium Already Afected By Destructive Disorder: Fibrillating Atria Conceptually Need Therapeutic Help Rather Than Surgical Or Ablative Destruction |
Q34660772 | Digoxin and mortality in atrial fibrillation: a prospective cohort study |
Q35102218 | Digoxin and risk of death in adults with atrial fibrillation: the ATRIA-CVRN study |
Q36321059 | Digoxin: A systematic review in atrial fibrillation, congestive heart failure and post myocardial infarction |
Q31156918 | Distinct risk factors of atrial fibrillation in patients with and without coronary artery disease: a cross-sectional analysis of the BOREAS-CAG Registry data |
Q57809106 | Do the benefits of anti-arrhythmic drugs outweigh the associated risks? A tale of treatment goals in atrial fibrillation |
Q31061099 | Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies |
Q34068742 | Dronedarone for the treatment of atrial fibrillation and atrial flutter: approval and efficacy |
Q42952490 | Dronedarone: NICE enough? |
Q47573550 | Dronedarone: a new hope for stroke prevention in atrial fibrillation? |
Q37736953 | Dronedarone: an emerging therapy for atrial fibrillation |
Q37899900 | Dronedarone: an overview |
Q34239793 | Dronedarone: evidence supporting its therapeutic use in the treatment of atrial fibrillation |
Q37767425 | Drug-induced QT-interval prolongation: considerations for clinicians |
Q37717862 | Drugs vs. ablation for the treatment of atrial fibrillation: the evidence supporting catheter ablation |
Q51120485 | Dual-chamber pacemakers as long-term telemetry devices: ready for prime-time in diagnosing unsuspected atrial fibrillation? |
Q39097180 | Early Cardioversion in Atrial Fibrillation: Earlier Is Better, but Not Always and (Maybe) Not Immediately |
Q37521378 | Early and comprehensive management of atrial fibrillation: proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'. |
Q35648223 | Early experience using a left atrial appendage occlusion device in patients with atrial fibrillation |
Q45960286 | Early increase of NOX2-derived oxidative stress in children: relationship with age. |
Q37737560 | Early management of atrial fibrillation: from imaging to drugs to ablation |
Q37495815 | Effect of Age on Outcomes of Catheter Ablation of Atrial Fibrillation |
Q47106384 | Effect of sinus rhythm restoration on markers of thrombin generation in atrial fibrillation |
Q36077080 | Effect of warfarin on outcomes in septuagenarian patients with atrial fibrillation |
Q47134346 | Effectiveness of catheter ablation of atrial fibrillation: are we at the dawn of a new era? |
Q36325590 | Efficacy and effects on cardiac function of radiofrequency catheter ablation vs. direct current cardioversion of persistent atrial fibrillation with left ventricular systolic dysfunction |
Q37650575 | Efficacy and safety of dronedarone: a review of randomized trials |
Q38386998 | Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation. |
Q51116249 | Efficacy of amiodarone in patients with atrial fibrillation with and without left ventricular dysfunction: a pooled analysis of AFFIRM and AF-CHF trials. |
Q59200971 | Eicosapentaenoic Acid for the Prevention of Recurrent Atrial Fibrillation |
Q36793204 | Electrical cardioversion for AF-the state of the art. |
Q24246610 | Electrical cardioversion for atrial fibrillation and flutter |
Q26796261 | European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society |
Q38571627 | European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. |
Q82079500 | Exercise heart rate acceleration patterns during atrial fibrillation and sinus rhythm |
Q37495738 | Exploring the Potential Role of Catheter Ablation in Patients with Asymptomatic Atrial Fibrillation: Should We Move away from Symptom Relief? |
Q94263931 | External electrical and pharmacological cardioversion for atrial fibrillation, atrial flutter or atrial tachycardias: a network meta‐analysis |
Q47663774 | Factors Associated with Anticoagulation Delay Following New-Onset Atrial Fibrillation. |
Q38897899 | Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism |
Q89320643 | Frequency of Cardiac Rhythm Abnormalities in a Half Million Adults |
Q50941064 | From left bundle branch block to Icelandic whales: the multiple perils of atrial fibrillation management in the elderly. |
Q36876093 | Genetic mechanisms of atrial fibrillation: impact on response to treatment |
Q38894994 | Genotype influence in responses to therapy for atrial fibrillation |
Q93160912 | Guideline-directed therapy at discharge in patients with heart failure and atrial fibrillation |
Q35138993 | Heart failure and atrial fibrillation: from basic science to clinical practice |
Q43918168 | Heart failure in patients with atrial fibrillation is associated with a high symptom and hospitalization burden: the RealiseAF survey |
Q30881762 | Heart failure prognosis and management in over-80-year-old patients: data from a French national observational retrospective cohort. |
Q35677371 | Heart rate is associated with progression of atrial fibrillation, independent of rhythm |
Q35036404 | Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial |
Q36021753 | How does Chronic Atrial Fibrillation Influence Mortality in the Modern Treatment Era? |
Q44054562 | How much atrial fibrillation causes symptoms of heart failure? |
Q55295121 | How to manage various arrhythmias and sudden cardiac death in the cardiovascular intensive care. |
Q36624404 | Impact of Awareness and Patterns of Nonhospitalized Atrial Fibrillation on the Risk of Mortality: The Reasons for Geographic And Racial Differences in Stroke (REGARDS) Study |
Q34146486 | Impact of age, CYP2C9 genotype and concomitant medication on the rate of rise for prothrombin time during the first 30 days of warfarin therapy |
Q36569905 | Impact of controlling atrial fibrillation on outcomes relevant to the patient: focus on dronedarone |
Q89878618 | Impact of the Fibrosis-4 Index on Risk Stratification of Cardiovascular Events and Mortality in Patients with Atrial Fibrillation: Findings from a Japanese Multicenter Registry |
Q36456002 | Implication from randomized trials of rate and rhythm controls on management of patients with persistent atrial fibrillation. |
Q35059670 | Improving ablation strategies for the treatment of atrial fibrillation |
Q53602857 | Inadvertent toxic drug reaction in the management of atrial fibrillation. |
Q37862925 | Incidental atrial fibrillation and its management |
Q35511302 | Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study |
Q37770108 | Interventional management of atrial fibrillation |
Q43858415 | Is appropriate management of atrial fibrillation in primary care a utopia? |
Q57214621 | Ischemic stroke risk during long-term follow up in patients with successful catheter ablation for atrial fibrillation in Korea |
Q57249882 | La fibrillation atriale est-elle un marqueur indépendant de risque cardio-vasculaire ? |
Q36860117 | Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial |
Q45034511 | Late thromboembolic events after circumferential pulmonary vein ablation of atrial fibrillation |
Q47263839 | Left Atrial Size and Left Ventricular End-Systolic Dimension Predict the Progression of Paroxysmal Atrial Fibrillation After Catheter Ablation. |
Q48184324 | Left atrial concomitant surgical ablation for treatment of atrial fibrillation in cardiac surgery: A meta-analysis of randomized controlled trials. |
Q126659203 | Lenient versus Strict Rate Control in Atrial Fibrillation |
Q39300535 | Lone AF - Etiologic Factors and Genetic Insights into Pathophysiolgy |
Q94595345 | Long-term Outcome of Pulmonary Vein Isolation Versus Amiodarone Therapy in Patients with Coexistent Persistent AF and Congestive Heart Failure |
Q44427484 | Long-term efficacy and safety of two different rhythm control strategies in elderly patients with symptomatic persistent atrial fibrillation |
Q81446072 | Long-term prognosis after cardioversion of the first episode of symptomatic atrial fibrillation: a condition believed to be benign revised |
Q39064825 | MEDEX South Carolina: a progress report |
Q39026788 | Management of Atrial Fibrillation in Elderly Adults |
Q51735257 | Management of Atrial Fibrillation. |
Q28217428 | Management of atrial fibrillation |
Q79917090 | Management of atrial fibrillation |
Q80815086 | Management of atrial fibrillation |
Q87752222 | Management of atrial fibrillation |
Q37417705 | Management of atrial fibrillation in patients with heart failure: from drug therapy to ablation. |
Q36441982 | Management of atrial fibrillation--what are the possibilities of early detection with home monitoring? |
Q35167436 | Management of patients with atrial fibrillation: specific considerations for the old age. |
Q38534063 | Management of tachycardia |
Q37115340 | Management of the Asymptomatic Patient After Catheter Ablation of Atrial Fibrillation |
Q38056113 | Management of ventricular and atrial arrhythmias in humans: towards a patient-specific approach |
Q52811915 | Management strategies for atrial fibrillation. |
Q35702394 | Managing atrial fibrillation in the elderly: critical appraisal of dronedarone |
Q37659215 | Managing atrial fibrillation in the global community: The European perspective |
Q36580667 | Medical management of atrial fibrillation: state of the art. |
Q91279118 | Meta-analysis of randomized controlled trials on atrial fibrillation ablation in patients with heart failure with reduced ejection fraction |
Q39036947 | Monitoring Atrial Fibrillation After Catheter Ablation. |
Q33768807 | Mortality, stroke, and heart failure in atrial fibrillation cohorts after ablation versus propensity-matched cohorts |
Q53318291 | Myocardial perfusion imaging does not adequately assess the risk of coronary artery disease in patients with atrial fibrillation. |
Q37697498 | New developments in atrial antiarrhythmic drug therapy |
Q37770107 | New-onset atrial fibrillation and acute coronary syndrome |
Q44846398 | New-onset atrial fibrillation is an independent predictor of in-hospital mortality in hospitalized heart failure patients: results of the EuroHeart Failure Survey |
Q36370426 | Non-pharmacological treatment of arrhythmias |
Q37551914 | Novel antiarrhythmic drugs in atrial fibrillation: focus on tedisamil |
Q37946861 | Novel anticoagulants for atrial fibrillation: a critical appraisal |
Q37481193 | Novel approaches for pharmacological management of atrial fibrillation. |
Q35489060 | Novel pharmacological targets for the rhythm control management of atrial fibrillation. |
Q42748645 | Opposing conclusions from post hoc analyses of the AFFIRM trial: was propensity score analysis to blame or just an innocent victim? |
Q37468892 | Optimization Of Stroke Prophylaxis Strategies In Nonvalvular AF -Drugs, Devices Or Both? |
Q36802853 | Optimization of Stroke Prophylaxis Strategies in Nonvalvular AF - Drugs, Devices or Both? |
Q37766393 | Optimizing the management of atrial fibrillation: focus on current guidelines and the impact of new agents on future recommendations |
Q36720925 | Overview of management of atrial fibrillation in symptomatic elderly patients: pharmacologic therapy versus AV node ablation |
Q46538287 | PAFAC Study. Secondary prevention of atrial fibrillation after cardioversion |
Q37338932 | Pathophysiology of concomitant atrial fibrillation and heart failure: implications for management |
Q37134738 | Patient preferences at ten years following initial diagnosis of atrial fibrillation: the Belgrade Atrial Fibrillation Study |
Q56864031 | Pharmacological therapy for atrial fibrillation: current options and new agents |
Q83866919 | Pharmacotherapy for atrial fibrillation: is rhythm control achievable? |
Q37123391 | Pharmacotherapy of atrial fibrillation: an old option with new possibilities |
Q60138050 | Point-by-point pulmonary vein antrum isolation guided by intracardiac echocardiography and 3D mapping and duty-cycled multipolar AF ablation: effect of multipolar ablation on procedure duration and fluoroscopy time |
Q38253047 | Prediction and personalised treatment of atrial fibrillation-stroke prevention: consolidated position paper of CVD professionals |
Q44754230 | Predictors and clinical implications of atrial fibrillation in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation. |
Q35151045 | Predictors and risk of pacemaker implantation after the Cox-maze IV procedure |
Q37252892 | Predictors of atrial fibrillation recurrence in patients with long-lasting atrial fibrillation |
Q89092899 | Predictors of oral anticoagulant non-prescription in patients with atrial fibrillation and elevated stroke risk |
Q34389483 | Present concepts in management of atrial fibrillation: From drug therapy to ablation |
Q84596232 | Pulmonary vein antrum isolation, atrioventricular junction ablation, and antiarrhythmic drugs combined with direct current cardioversion: survival rates at 7 years follow-up |
Q37656335 | Pulmonary vein isolation for the treatment of atrial fibrillation: past, present and future |
Q90467854 | Pulmonary vein volume predicts the outcome of radiofrequency catheter ablation of paroxysmal atrial fibrillation |
Q42359516 | Putative Role of Right Atrial Ablation in Atrial Fibrillation |
Q36147009 | Radiofrequency Catheter Ablation Improves the Quality of Life Measured with a Short Form-36 Questionnaire in Atrial Fibrillation Patients: A Systematic Review and Meta-Analysis |
Q37496104 | Rate Control in Atrial Fibrillation: Avoiding Morbidity |
Q33585592 | Rate Versus Rhythm Control Pharmacotherapy For Atrial Fibrillation: Where are We in 2008? |
Q38936964 | Rate control in atrial fibrillation |
Q35773042 | Rate control in the medical management of atrial fibrillation |
Q36077780 | Rate control vs. rhythm control in the management of atrial fibrillation in elderly persons |
Q36214675 | Rate versus rhythm control in patients with atrial fibrillation: what the trials really say. |
Q36269171 | Rate versus rhythm control in the management of patients with atrial fibrillation |
Q51361316 | Rate versus rhythm control strategies for AF. |
Q46167374 | Rate versus rhythm control with and without heart failure |
Q28200383 | Rate-control or rhythm-control: where do we stand? |
Q37283337 | Rate-control versus rhythm-control strategies and outcomes in septuagenarians with atrial fibrillation |
Q27692632 | Rationale and current perspective for early rhythm control therapy in atrial fibrillation. |
Q38881287 | Reframing the association and significance of co-morbidities in heart failure |
Q34161171 | Responsiveness of AF6, a new, short, validated, atrial fibrillation-specific questionnaire--symptomatic benefit of direct current cardioversion |
Q79414555 | Restoring normal sinus rhythm in atrial fibrillation : evidence from pharmacologic therapy and catheter ablation trials |
Q37845022 | Review of contemporary antiarrhythmic drug therapy for maintenance of sinus rhythm in atrial fibrillation |
Q38199620 | Revisiting heart activation-conduction physiology, part I: atria. |
Q92277166 | Rhythm Control in AF: Have We Reached the Last Frontier? |
Q92219072 | Rhythm Management of the Atrial Fibrillation Patient: Practical Implementation of the 2012 ESC Guidelines |
Q37812344 | Rhythm control strategies and the role of antiarrhythmic drugs in the management of atrial fibrillation: focus on clinical outcomes |
Q37496212 | Risks from Catheter Ablation of Atrial Fibrillation: A Review of Methods, Efficacy, and Safety |
Q64072391 | Rivaroxaban in atrial fibrillation cardioversion: an update |
Q37013005 | Robotic and magnetic navigation for atrial fibrillation ablation. How and why? |
Q28075507 | Robotic magnetic navigation for ablation of human arrhythmias |
Q38528051 | Robotic navigation for catheter ablation: benefits and challenges. |
Q42925101 | Role of Dronedarone in Atrial Fibrillation: More Questions Than Answers |
Q33809189 | Serological predictors for the recurrence of atrial fibrillation after electrical cardioversion |
Q38011970 | Should rhythm control be preferred in younger atrial fibrillation patients? |
Q37831854 | Sinus rhythm restoration and treatment success: insight from recent clinical trials. |
Q35989632 | Stroke prevention in atrial fibrillation: warfarin faces its challengers |
Q37293140 | Structural remodeling in atrial fibrillation. |
Q92703557 | Subclinical and Asymptomatic Atrial Fibrillation: Current Evidence and Unsolved Questions in Clinical Practice |
Q38685823 | Successful recovery of tachycardia-induced cardiomyopathy with severely depressed left ventricular systolic function by catheter ablation with mechanical hemodynamic support: a case report |
Q30479334 | Surgery for Lone Atrial Fibrillation: Present State-of-the-Art |
Q27022070 | Surgery for atrial fibrillation |
Q35062034 | Surgical options in atrial fibrillation |
Q38119110 | Surgical techniques used for the treatment of atrial fibrillation |
Q89284209 | Sustained atrial fibrillation increases the risk of anticoagulation-related bleeding in heart failure |
Q37523118 | Systematic review and meta-analysis of surgical ablation for atrial fibrillation during mitral valve surgery |
Q64074292 | The Evolving Role of Catheter Ablation in Patients With Heart Failure and AF |
Q92434811 | The Impact of Repeated Cardioversions for Atrial Fibrillation on Stroke, Hospitalizations, and Catheter Ablation Outcomes |
Q26747263 | The Mechanism of and Preventive Therapy for Stroke in Patients with Atrial Fibrillation |
Q36264955 | The Role of Pharmacogenetics in Atrial Fibrillation Therapeutics: Is Personalized Therapy in Sight? |
Q35197116 | The burden of atrial fibrillation in the Netherlands |
Q39119910 | The burden of proof: The current state of atrial fibrillation prevention and treatment trials |
Q38194112 | The efficacy and tolerability of commonly used agents to prevent recurrence of atrial fibrillation after successful cardioversion |
Q37402218 | The emerging role of antiarrhythmic compounds with atrial selectivity in the management of atrial fibrillation |
Q35205261 | The impact of CHADS2 score on late stroke after the Cox maze procedure |
Q90422408 | The impact of body weight and diabetes on new-onset atrial fibrillation: a nationwide population based study |
Q37968514 | The management of patients with atrial fibrillation and dronedarone's place in therapy |
Q46184672 | The prevalence of sinus rhythm in patients with "permanent" atrial fibrillation |
Q79370892 | The prognostic impact of successful cardioversion of atrial fibrillation in patients with organic heart disease |
Q57449367 | The role of the gap junction perinexus in cardiac conduction: Potential as a novel anti-arrhythmic drug target |
Q36446911 | The safety of digoxin as a pharmacological treatment of atrial fibrillation. |
Q84588920 | The surgical treatment of atrial fibrillation |
Q36764580 | The worldwide social burden of atrial fibrillation: what should be done and where do we go? |
Q26828753 | The year in review of clinical cardiac electrophysiology |
Q57627876 | Therapie von Vorhofflimmern |
Q37847185 | Treating arrhythmias: an expert opinion |
Q37496298 | Treatment Considerations for a Dual Epidemic of Atrial Fibrillation and Heart Failure |
Q39195789 | Treatment Failure With Rhythm and Rate Control Strategies in Patients With Atrial Fibrillation and Congestive Heart Failure: An AF-CHF Substudy |
Q34884620 | Treatment of atrial fibrillation in every days practice |
Q34307919 | Trends in the use of electrical cardioversion for atrial fibrillation: influence of major trials and guidelines on clinical practice |
Q34505579 | Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation |
Q37126166 | Update on atrial fibrillation: part II. |
Q35926637 | Upstream therapeutic strategies of Valsartan and Fluvastatin on Hypertensive patients with non-permanent Atrial Fibrillation (VF-HT-AF): study protocol for a randomized controlled trial |
Q36437128 | Upstream therapy with statin and recurrence of atrial fibrillation after electrical cardioversion. Review of the literature and meta-analysis |
Q37278794 | Validity and reliability of a new, short symptom rating scale in patients with persistent atrial fibrillation |
Q36764028 | Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent |
Q47593262 | WITHDRAWN: Electrical cardioversion for atrial fibrillation and flutter. |
Q38384893 | What can rhythm control therapy contribute to prognosis in atrial fibrillation? |
Q81356754 | When, how, and why should sinus rhythm be restored in patients with persistent atrial fibrillation? |
Q87301012 | [Medicinal rate control in atrial fibrillation] |
Q82654632 | [Rhythm control - cardioversion] |
Q82654665 | [Which therapy for which patient? In daily practice] |
Search more.